GlassScriptPhysician profile
Emily Shipman
NPI 1750097119
$3,429.34
in general payments reported to CMS, 2019-2025
28 companies · $2,371 in 2025
The $2,371 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $471 · 2024: $588 · 2025: $2,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,165 · Travel and Lodging: $1,228 · Education: $36.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,165.44 |
| Travel and Lodging | $1,227.90 |
| Education | $36.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,591.21 | 2025 | Interstim |
| 180 Medical, INC. | $191.34 | 2023-2025 | Gentlecath, Gentlecath Glide |
| Abbvie INC. | $160.98 | 2023-2024 | |
| Astellas Pharma US INC | $148.45 | 2024-2025 | Xtandi |
| Sumitomo Pharma America, INC. | $136.64 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $133.86 | 2024-2025 | |
| Janssen Biotech, INC. | $132.41 | 2023-2025 | Erleada, Akeega |
| Accord Healthcare, INC. | $105.67 | 2025 | |
| Boston Scientific Corporation | $104.75 | 2023 | Spaceoar Vue System - 10ml |
| Astrazeneca Pharmaceuticals LP | $69.24 | 2023-2025 | Lynparza, Faslodex |
| Endo USA, INC. | $68.36 | 2024-2025 | Xiaflex, Aveed |
| Laborie Medical Technologies Corp. | $67.84 | 2024-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Dendreon Pharmaceuticals LLC | $64.93 | 2023 | Provenge |
| Myriad Genetic Laboratories, INC. | $59.37 | 2023 | Prolaris |
| Urogen Pharma, INC. | $57.18 | 2023-2025 | Jelmyto |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $46.20 | 2025 | Adstiladrin |
| Novartis Pharmaceuticals Corporation | $38.75 | 2025 | |
| Sun Pharmaceutical Industries INC. | $31.65 | 2024 | |
| Progenics Pharmaceuticals, INC. | $27.78 | 2024 | |
| Amgen INC. | $27.67 | 2023 | Xgeva |
| Merck Sharp & Dohme LLC | $26.98 | 2024 | Keytruda, Welireg |
| Teleflex LLC | $25.28 | 2025 | Urolift |
| Abc Home Medical Supply, INC. | $24.69 | 2024 | |
| Olympus America INC. | $21.79 | 2025 | Itind System |
| Photocure INC | $19.05 | 2023 | Cysview |
| Endo Pharmaceuticals INC. | $18.69 | 2023 | Xiaflex, Aveed |
| Tolmar, INC. | $15.10 | 2023 | |
| Halozyme INC | $13.48 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Shipman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.